NCT07114614Recruiting
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
The purpose of this research study is to investigate whether cancer survivors have higher levels of proteins called Fatty Acid Binding Proteins as well as 12 different markers of cellular senescence than people who have never had cancer. Investigators believe that these levels may be elevated in cancer survivors as a result of their cancer and the treatments they received and may put them at higher risk for chronic conditions such as high cholesterol, diabetes, high blood pressure, and obesity. This study will also compare the levels of these proteins and inflammatory markers in the blood with different aspects of cancer treatment the survivors received. Investigators are investigating if there is a correlation between levels of these proteins and markers, the type of treatment cancer survivors received, and development of metabolic conditions.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 4 Aug 2025
- Start date
- Sept 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Case Comprehensive Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT07114614
What you commit to
- Study type: Observational
- Planned participants: 120
- From Sept 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking systemic steroids and/or immunosuppressant medications
- Acute illness necessitating hospitalization in the 30 days prior to blood draw
- A diagnosis of Type 2 diabetes or Hypertension treated with medication
- Currently lipid lowering medications
Other illness
- Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months
- Presence of active graft versus host disease
- Malignancy treated using surgery only
- Acute relapsed disease or second malignancy
- Transplant for non-malignant conditions (e.g. cell disease, Hurler syndrome)
- Presence of a chronic inflammatory disease EXCEPT obesity
- Fever, active infection or inflammation, or taking antibiotics at the time of blood draw
Other
- Pregnancy at the time of the study
- Growth hormone deficiency or hypothalamic dysfunction
Who the study is looking for
- Diagnosis of at least one malignancy for which chemotherapy, radiation, and/or stem cell transplantation was utilized as part of treatment
- Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy
- At least 1-year post-stem cell transplant for malignant condition
Age in the registry: 5 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Case Comprehensive Cancer Center, UH Rainbow Babies & Children's Hospital Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.